Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-02-27 @ 9:05 AM
Study NCT ID:
NCT00251394
Status:
COMPLETED
Last Update Posted:
2010-01-29
First Post:
2005-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
03-411
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Arnold Freedman, MD
Old Organization:
Dana-Farber Cancer Institute